Alimera Sciences   Report issue

For profit Phase 4
Founded: Alpharetta GA United States (2003)
Status: No NME R&D (2003)

Organization Overview

First Clinical Trial
2007
NCT00490815
First Marketed Drug
2014
fluocinolone acetonide (synalar)
First NDA Approval
None
Last Known Activity
2020

Timeline

NOW
  • Now

Alternative names

Alimera Sciences | Alimera Sciences, Inc. | ALIMERA SCIENCES INC

Active Ingredients

Marketed Drugs (1)

fluocinolone acetonide (synalar) (2014)

Drugs in Phase 4 Trials (2)

aflibercept (zaltrap) (1 trial)

fluocinolone acetonide (synalar) (9 trials)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Atrophy (Phase 2)

Edema (Phase 4)

Geographic Atrophy (Phase 2)

Macular Degeneration (Phase 2)

Macular Edema (Phase 4)

Retinal Vein Occlusion (Phase 2)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 9
  • # of Trial APIs: 2